2025 H2 -tulosraportti
141 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·7 t sittenThe most interesting thing is not the capital raise itself of $315 million, but what the money will be used for. 1. AdvanCell is already a customer of Thor Medical This is the most important connection. Thor Medical and AdvanCell extended their supply agreement for Thorium-228 in 2025, where the total purchase commitment increased from 100 to 150 million kroner, while the delivery volume was increased by 50 %. thormedical.com 2. The entire investment is intended to accelerate what Thor Medical delivers to In the article, AdvanCell states that the capital will be used to: take ADVC001 into phase 3, build American production capacity, expand the production of Pb-212, strengthen the isotope supply chain. fiercebiotech.com +1 This is exactly where Thor Medical comes in. 3. Thorium-228 is the raw material AdvanCell's technology is based on Lead-212 (Pb-212). Pb-212 is produced from Thorium-228 in their generator platform. AdvanCell itself has previously highlighted that Th-228 is the key material for scaling Pb-212 production. AdvanCell In other words: More Pb-212 production → greater need for Th-228. 4. The risk is reduced A financing round of $315 million increases the likelihood that AdvanCell will actually carry out: phase 3, scaling up production, commercial launch. It also makes them appear as a more robust and long-term customer for Thor Medical. fiercebiotech.com +1 5. A signal about the entire market The article also shows that investors are heavily betting on targeted alpha therapy. AdvanCell itself describes the field as being at a turning point, and points out that the biggest bottleneck is isotope access and production capacity. fiercebiotech.com +1 It is precisely this bottleneck that Thor Medical is trying to solve. My assessment For Thor Medical, this is probably more than just "good news from a customer". It is one of the clearest signals so far that one of their largest partners: has secured financing, increases the likelihood of commercial production, and thus increases the likelihood of increased demand for Thorium-228 over time. This does not mean that Thor Medical automatically gets new contracts or higher revenues immediately. But strategically, this financing strengthens the investment case because it reduces customer and execution risk at one of the company's most important partners.
·1 päivä sittenWaiting for payday, then there will be an entry here❤️👍 (If I make it before this takes off😏❤️
Had faith in this stock half a year ago. Then there was a small but steady increase upwards. Since then, everyone has hyped it up and it has only gone down. Might as well and sell at break-even. ..- 1 päivä sitten
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
141 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenThe most interesting thing is not the capital raise itself of $315 million, but what the money will be used for. 1. AdvanCell is already a customer of Thor Medical This is the most important connection. Thor Medical and AdvanCell extended their supply agreement for Thorium-228 in 2025, where the total purchase commitment increased from 100 to 150 million kroner, while the delivery volume was increased by 50 %. thormedical.com 2. The entire investment is intended to accelerate what Thor Medical delivers to In the article, AdvanCell states that the capital will be used to: take ADVC001 into phase 3, build American production capacity, expand the production of Pb-212, strengthen the isotope supply chain. fiercebiotech.com +1 This is exactly where Thor Medical comes in. 3. Thorium-228 is the raw material AdvanCell's technology is based on Lead-212 (Pb-212). Pb-212 is produced from Thorium-228 in their generator platform. AdvanCell itself has previously highlighted that Th-228 is the key material for scaling Pb-212 production. AdvanCell In other words: More Pb-212 production → greater need for Th-228. 4. The risk is reduced A financing round of $315 million increases the likelihood that AdvanCell will actually carry out: phase 3, scaling up production, commercial launch. It also makes them appear as a more robust and long-term customer for Thor Medical. fiercebiotech.com +1 5. A signal about the entire market The article also shows that investors are heavily betting on targeted alpha therapy. AdvanCell itself describes the field as being at a turning point, and points out that the biggest bottleneck is isotope access and production capacity. fiercebiotech.com +1 It is precisely this bottleneck that Thor Medical is trying to solve. My assessment For Thor Medical, this is probably more than just "good news from a customer". It is one of the clearest signals so far that one of their largest partners: has secured financing, increases the likelihood of commercial production, and thus increases the likelihood of increased demand for Thorium-228 over time. This does not mean that Thor Medical automatically gets new contracts or higher revenues immediately. But strategically, this financing strengthens the investment case because it reduces customer and execution risk at one of the company's most important partners.
- ·1 päivä sittenWaiting for payday, then there will be an entry here❤️👍 (If I make it before this takes off😏❤️Had faith in this stock half a year ago. Then there was a small but steady increase upwards. Since then, everyone has hyped it up and it has only gone down. Might as well and sell at break-even. ..
- 1 päivä sitten
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
141 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenThe most interesting thing is not the capital raise itself of $315 million, but what the money will be used for. 1. AdvanCell is already a customer of Thor Medical This is the most important connection. Thor Medical and AdvanCell extended their supply agreement for Thorium-228 in 2025, where the total purchase commitment increased from 100 to 150 million kroner, while the delivery volume was increased by 50 %. thormedical.com 2. The entire investment is intended to accelerate what Thor Medical delivers to In the article, AdvanCell states that the capital will be used to: take ADVC001 into phase 3, build American production capacity, expand the production of Pb-212, strengthen the isotope supply chain. fiercebiotech.com +1 This is exactly where Thor Medical comes in. 3. Thorium-228 is the raw material AdvanCell's technology is based on Lead-212 (Pb-212). Pb-212 is produced from Thorium-228 in their generator platform. AdvanCell itself has previously highlighted that Th-228 is the key material for scaling Pb-212 production. AdvanCell In other words: More Pb-212 production → greater need for Th-228. 4. The risk is reduced A financing round of $315 million increases the likelihood that AdvanCell will actually carry out: phase 3, scaling up production, commercial launch. It also makes them appear as a more robust and long-term customer for Thor Medical. fiercebiotech.com +1 5. A signal about the entire market The article also shows that investors are heavily betting on targeted alpha therapy. AdvanCell itself describes the field as being at a turning point, and points out that the biggest bottleneck is isotope access and production capacity. fiercebiotech.com +1 It is precisely this bottleneck that Thor Medical is trying to solve. My assessment For Thor Medical, this is probably more than just "good news from a customer". It is one of the clearest signals so far that one of their largest partners: has secured financing, increases the likelihood of commercial production, and thus increases the likelihood of increased demand for Thorium-228 over time. This does not mean that Thor Medical automatically gets new contracts or higher revenues immediately. But strategically, this financing strengthens the investment case because it reduces customer and execution risk at one of the company's most important partners.
- ·1 päivä sittenWaiting for payday, then there will be an entry here❤️👍 (If I make it before this takes off😏❤️Had faith in this stock half a year ago. Then there was a small but steady increase upwards. Since then, everyone has hyped it up and it has only gone down. Might as well and sell at break-even. ..
- 1 päivä sitten
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt